Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carrick Therapeutics Lays Foundation For 'Leading Oncology Business'

Executive Summary

With $95m in the bank from various investors – including ARCH Ventures, Woodford Investment Management, Google Ventures and drug discovery company Evotec – recently launched Carrick Therapeutics is striving to be at the forefront of oncology companies in Europe.

You may also be interested in...



Start-Up Quarterly Statistics, Q4 2016

A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus

ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL021103

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel